UPLC-MS/MS测定人血浆中咪达那新的浓度及其生物等效性研究
Determination of imidafenacin in human plasma by UPLC-MS/MS and its bioequivalence
-
摘要: 用UPLC-MS/MS测定人血浆中咪达那新的浓度，并应用于咪达那新片在中国健康受试者中的药代动力学及生物等效性研究。采用Acquity UPLC BEH C8(2.1 mm×50 mm，1.7 μm)色谱柱，流动相A为2 mmol/L乙酸铵溶液(含0.2%乙酸)，B为乙腈，梯度洗脱。采用液液萃取的前处理方法减小血浆样品的基质效应。质谱条件为正离子模式，咪达那新和咪达那新-d10 的检测离子分别为m/z 320.2→238.1和m/z 330.2→248.2。临床试验采用单剂量双周期自身交叉试验设计，24例健康受试者空腹条件下口服咪达那新片参比制剂或受试制剂。使用上述检测方法检测生物样品中咪达那新的含量，后用DAS3.2.8软件进行药代动力学及生物等效研究。咪达那新在10.0~1 000 pg/mL范围内线性良好，低、中、高浓度的样品提取回收率分别为84.0%、88.0%、90.0%，基质效应分别为105%、100%、101%。参比及受试制剂的药代动力学参数cmax分别为524.8和612.6 pg/mL，tmax分别为1.250和1.063 h，AUC0-∞分别为2 229和2 466 pg/mL·h，参比制剂及受试制剂生物等效。
-
关键词:
- 咪达那新 /
- 超高效液相色谱串联质谱法 /
- 药代动力学
Abstract: A sensitive and selective method for the determination of imidafenacin in human plasma using liquid chromatography combined with mass spectrometry was established, and was applied to the pharmacokinetic and bioequivalence studies of imidafenacin in healthy Chinese volunteers. After the liquid-liquid extraction pretreatment, samples were separated by UPLC on BEH C8(2. 1 mm×50 mm, 1. 7 μm)column with mobile phase 2 mmol/L ammonium acetate solution with 0. 2% acetic acid and acetonitrile using gradient elution. The mass instrument was operated in the positive ion mode, and the monitored transition was set at m/z 320. 2→238. 1 and m/z 330. 2→248. 2 for imidafenacin and IS(imidafenacin-d10), respectively. In the single-dose, double cycle, self-crossover clinical trial, 24 healthy Chinese volunteers received 0. 1 mg reference or test imidafenacin tablet orally under fasting condition. Drug concentration in plasma was determined by this method and the pharmacokinetic parameters were calculated by DAS 3. 2. 8 software. The linear range of the analysis method is 10. 0 pg/mL to 1 000 pg/mL. The extraction recoveries of the low medium and high concentration samples were 84. 0%, 88. 0% and 90. 0%, respectively. The matrix effects of low medium and high concentration samples were 105%, 100% and 101%, respectively. The pharmacokinetic parameters of imidafenacin for the reference and test tablets were as follows: cmax 524. 8 pg/mL vs 612. 6 pg/mL, tmax 1. 250 h vs 1. 063 h, AUC0-∞ 2 229 pg ·h/mL vs 2 466 pg ·h/mL. The reference and test tablets of imidafenacin were bioequivalent. This method proved to be rapid and accurate for the pharmacokinetic and bioequivalence studies of imidafenacin.-
Keywords:
- imidafenacin /
- UPLC-MS/MS /
- pharmacokinetics
-
-
[1] Guo H,Zhang YQ.New drug for overactive bladder:imidafenacin[J].Qilu Pharm Aff(齐鲁药事),2008,27(5):317-318. [2] Zhang Y.Synthesis research progress of imidafenacin[J].J Chem Ind & Eng(化学工业与工程技术),2004,35(3):59-61. [3] Liu SH. Clinical characteristics of bladder overactivity and its advances in drug therapy[J].J Med Theory Pract(医学理论与实践),2018,31(5):653-654. [4] Zhang Y.Research progress of imidafenacin[J].Zhejiang Chem Ind(浙江化工),2015,46(2):14-17. [5] Lee KS,Park B,Kim JH,et al.A randomised,double-blind,parallel design,multi-institutional,non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder[J].Int J Clin Pract,2013,67(12):1317-1326. [6] Sakakibara R,Hamano H,Yagi H.Cognitive safety and overall tolerability of imidafenacin in clinical use:a long-term,open-label,post-marketing surveillance study[J].Lower Urinary Tract Symptoms,2014,6(3):138-144. [7] Masumori N.Long-term safety,efficacy,and tolerability of imidafenacin in the treatment of overactive bladder:a review of the Japanese literature[J].Patient Prefer Adherence,2013,7:111-120. [8] Uchida H,Otsuka M.Quantitative analysis of pseudopolymorphic transformation of imidafenacin by application of a novel combination of near-infrared spectroscopy and a humidity-controlled 96-well plate[J].J Pharm Pharmacol,2011,63(7):911-917. [9] Ohmori S,Miura M,Toriumi C,et al.Absorption,metabolism,and excretion of [14C]imidafenacin,a new compound for treatment of overactive bladder,after oral administration to healthy male subjects[J].Drug Metab Dispos,2007,35(9):1624-1633. [10] Otsuka A,Kageyama S,Suzuki T,et al.Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder:a randomized controlled trial(COMFORT study)[J].Int J Urol,2016,23(12):1016-1023. [11] Nakade S,Ohno T,Nakayama K,et al.No effect of imidafenacin,a novel antimuscarinic drug,on digoxin pharmacokinetics in healthy subjects[J].Drug Metab Pharmacokinet,2008,23(2):95-100. [12] Ohno T,Nakade S,Nakayama K,et al.Absolute bioavailability of imidafenacin after oral administration to healthy subjects[J].Br J Clin Pharmacol,2008,65(2):197-202. [13] Hu YY,Shen L,Wang LP,et al.A liquid chromatography-tandem mass spectrometry method for the quantitation of imidafenacin in human plasma:application to a clinical pharmacokinetic study[J].Anal Methods,2016,8(38):6903-6908. [14] Hasegawa C,Ohno T,Nakade S,et al.Population pharmacokinetics and exposure-response relationship of a muscarinic receptor antagonist,imidafenacin[J].Drug Metab Pharmacokinet,2013,28(3):203-212. [15] Xiao YY,Ma PC,Wang Y,et al.Determination of 8′-hydroxy-dihydroergocryptine in human plasma by LC-MS/MS and its application to a bioequivalence evaluation[J].J China Pharm Univ(中国药科大学学报),2012,43(2):177-181. [16] Liang F,Li D,Wang RB,et al.Pharmacokinetics and absolute bioavailability of isoschaftoside in rat by LC-MS/MS[J].J China Pharm Univ(中国药科大学学报),2019,50(1):75-80. -
期刊类型引用(2)
1. 单娜，张丽，郭剑，余婧，汪莎，党艳妮，王晓梅，安莉，李传玲，徐秋瑾，常梦琦，于栋梁，刘峰. 咪达那新片在中国健康受试者生物等效性研究. 中国临床药理学杂志. 2022(01): 60-64 . 
百度学术
2. 施晓露，乔宏伟，吴健美，狄斌，王优美. 毛发中地佐辛、杜冷丁的UPLC-MS/MS检测. 中国药科大学学报. 2022(01): 74-78 . 本站查看
其他类型引用(0)
计量
- 文章访问数:
- HTML全文浏览量: 0
- PDF下载量:
- 被引次数: 2
下载:
